Inovio Pharmaceuticals NASDAQ: INO is preparing to launch its first approved product, VOCERYQ, after the U.S. Food and Drug Administration granted accelerated approval for the treatment of adults with recurrent respiratory papillomatosis, or RRP.
President and CEO Jacqueline Shea said the company expects to ship the product within 60 days of its October 30 approval and have its full field force deployed in the first quarter of next year. Inovio is working with Syneos Health on the field deployment.
VOCERYQ is approved to reduce the frequency of surgery in adults with RRP, a rare disease in which human papillomavirus, or HPV, causes wart-like growths in the respiratory tract. Shea said repeated surgery has been the standard of care, but procedures can damage the vocal cords and affect patients’ ability to speak.
Clinical Results and Treatment
VOCERYQ is regulated in the U.S. as a combination product, consisting of two DNA plasmids administered with Inovio’s CELLECTRA 5PSP delivery device. One plasmid encodes antigens from the HPV types that cause RRP, while the other encodes human IL-12, an immune adjuvant intended to enhance the response, Shea said.
The treatment regimen consists of four doses over nine weeks. In a Phase 1/2 trial, patients had undergone at least two surgeries in the year before treatment. The study did not require additional surgeries during the dosing window, and surgeries after treatment were counted toward the efficacy endpoint, Shea said.
In the first year, 72% of patients had a reduction in surgeries of at least 50% compared with the year before treatment, and 28% required no surgery, according to Shea. In a retrospective follow-up, 86% had a reduction of at least 50% in the second year, while 50% required no surgery. Shea described the safety profile as well tolerated, with a low rate of systemic adverse events.
For the accelerated approval analysis, the FDA evaluated patients who had undergone at least three surgeries in the year before treatment. Among that group, 27% required no surgeries in the 12 months following completion of treatment, Shea said.
Launch Plans and Market Opportunity
Inovio estimates that approximately 25,000 people in the U.S. have active RRP, based on claims database analysis. Shea said most patients are still managed surgically and that only a fraction have received immunotherapy.
Inovio aims to have payer policies covering 80% of patients within nine months of approval. Shea said the company’s planned field force should cover approximately 90% of the RRP patient opportunity. About 400 U.S. laryngologists treat the vast majority of patients with the condition, she added.
Shea said Inovio believes VOCERYQ could become a preferred first-line immunotherapy, citing its dosing regimen, tolerability and potential for administration in a physician’s office. She also noted that another immunotherapy has recently been approved for RRP.
Pipeline and Financial Position
Inovio plans to explore continued VOCERYQ treatment, pediatric use and expansion into additional geographic markets. Shea said the company had submitted a conditional marketing authorization application to the European Medicines Agency.
Beyond VOCERYQ, Inovio’s pipeline includes INO-3112 for HPV-positive head and neck cancer and INO-5412 for glioblastoma. The company is also seeking partners for preclinical programs in hemophilia A, Fabry disease and hypophosphatasia.
Shea said Inovio’s current cash and equivalents would fund operations through the end of the fourth quarter of next year without additional fundraising or revenue. She added that the company has no debt on its balance sheet.
About Inovio Pharmaceuticals (NASDAQ:INO)
Inovio Pharmaceuticals, Inc. is a biotechnology company developing DNA medicines, including treatments intended to stimulate the body's immune response to cancers and infectious diseases. Its research has focused on therapeutic and preventive applications, with candidates targeting conditions such as human papillomavirus (HPV)-related disease. The company's technology uses synthetic DNA plasmids designed to prompt cells to produce targeted antigens. Inovio has also developed its CELLECTRA platform, which uses electroporation to help deliver DNA medicines into cells.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Inovio Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inovio Pharmaceuticals wasn't on the list.
While Inovio Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.